Table 2.

Adverse events leading to treatment discontinuation

Patients, n (%)	G-FC (n = 21)	G-B (n = 20)
Total number of patients with at least 1 adverse event leading to discontinuation	7 (33)	2 (10)
Overall total number of events	9	2
Neutropenia	3 (15)	2 (10)
Pancytopenia	1 (5)	0
Thrombocytopenia	2 (10)	0
ALT/AST increased	2 (10)	0
Cellulitis	1 (5)	0

ALT, alanine aminotransferase; AST, aspartate aminotransferase.